Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics is attractive because its DRP platform adds a precision-medicine edge that can improve patient selection and increase the odds of clinical benefit for stenoparib, its lead asset in ovarian cancer and newly expanded into recurrent SCLC. The fundamental case is strengthened by encouraging Phase 2 data, including median overall survival exceeding 25 months in advanced ovarian cancer and two patients benefiting for more than 29 months as of March 2026, alongside a broad PARP inhibitor market that generated about $9.0 billion in 2023 and may exceed $21.0 billion by 2031. Although the company remains early-stage and loss-making, the improved 2026 EPS estimate to $(0.80), plus $20 million in cash and $22 million in debt in Q1 with liquidity expected into 2028, supports a favorable risk-reward profile.

Allarity Therapeutics is exposed to substantial fundamental risk because its value depends on a single clinical-stage oncology program, stenoparib, whose safety, efficacy, and regulatory acceptance remain unproven. The company also relies on its DRP companion diagnostic to improve patient selection, but any failure to demonstrate clear clinical benefit or to secure and maintain approvals could undermine commercialization prospects. In addition, balance sheet and liquidity pressures, reimbursement uncertainty, competition, and weak biotech investor sentiment create material downside risk to the business’s ability to fund development and convert its ovarian cancer focus into revenue.